SCHEMBL424536

SCHEMBL424536

CNS(=O)(=O)c1cc[c]c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA3 P07451 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA5A P35218 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA13 Q8N1Q1 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5B Q9Y2D0 2/20 0.41
TAS2R14 Q9NYV8 1/20 0.41
KIF11 P52732 1/20 0.41
HTT P42858 1/20 0.40
TNNI3K Q59H18 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090626 0.79 LMNA (0.46) LMNAL3MBTL1SMN1; SMN2GAACA12
SCHEMBL1447811 0.79 PTGS2 (0.38) LMNASMN1; SMN2KIF11PTGS2
SCHEMBL6319405 0.78 CA12 (0.50) LMNAL3MBTL1SMN1; SMN2GAACA12
SCHEMBL3810665 0.75 ALDH1A1 (0.39) LMNASMN1; SMN2CA12CA1CA2
SCHEMBL2895869 0.75 CA2 (0.47) LMNAGAACA12CA1CA2
SCHEMBL16880017 0.74 HRH4 (0.33) SMN1; SMN2
SCHEMBL9320310 0.73 CA1 (0.53) LMNAL3MBTL1SMN1; SMN2GAACA12
SCHEMBL167548 0.71 SMN1; SMN2 (0.58) LMNAL3MBTL1SMN1; SMN2GAACA12
SCHEMBL425487 0.71 KMT2A (0.58) LMNAL3MBTL1SMN1; SMN2GAACA12
SCHEMBL15015953 0.70 TNNI3K (0.43) LMNAL3MBTL1SMN1; SMN2GAACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2239253-B1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-06-19 EP disclosed
US-8415359-B2 Phenylpyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-04-09 US disclosed
US-20120022075-A1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-26 US disclosed
US-8017610-B2 Phenylpyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-09-13 US disclosed
US-20110003787-A1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-01-06 US disclosed
EP-2239253-A1 NOVEL PHENYLPYRROLE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003787-A1 NOVEL PHENYLPYRROLE DERIVATIVE GCKR, GCK, SLC5A1 LMNA 4848/4885L3MBTL1 3855/4885SMN1; SMN2 3765/4885
US-20120022075-A1 NOVEL PHENYLPYRROLE DERIVATIVE GCKR, GCK, SLC5A1 LMNA 4848/4885L3MBTL1 3855/4885SMN1; SMN2 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.